• BG Medicine Inc., of Waltham, Mass., said results of a research study conducted at the Massachusetts General Hospital provided additional evidence that elevated levels of galectin-3 predict adverse outcomes in chronic heart failure and suggested the prognostic value of the noninvasive biomarker may be enhanced when serial measurements are made over time.